Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest Update

Key Points

• Taysha Gene Therapies, Inc. saw a significant increase in short interest in July, rising by 2,952.8% to a total of 43,960,000 shares.
• Despite recent losses, several analysts maintain positive outlooks for TSHA, with a consensus target price of $8.17 and multiple firms providing "buy" ratings.
• Major shareholder Paul B. Manning increased his stake in Taysha by acquiring 750,000 shares at an average cost of $2.75 per share.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 43,960,000 shares, anincreaseof2,952.8% from the June 30th total of 1,440,000 shares. Based on an average daily trading volume, of 3,860,000 shares, the short-interest ratio is currently 11.4 days. Based on an average daily trading volume, of 3,860,000 shares, the short-interest ratio is currently 11.4 days.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TSHA shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. JMP Securities raised their target price on Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a report on Thursday, May 29th. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Chardan Capital raised their target price on Taysha Gene Therapies from $7.00 to $9.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Finally, Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, July 1st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $8.17.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA traded up $0.01 during midday trading on Friday, reaching $2.74. 949,352 shares of the company traded hands, compared to its average volume of 2,883,648. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $3.31. The firm has a market capitalization of $587.10 million, a price-to-earnings ratio of -7.93 and a beta of 0.97. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.35 and a quick ratio of 5.35. The company has a fifty day moving average price of $2.58 and a 200 day moving average price of $2.02.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). Taysha Gene Therapies had a negative return on equity of 104.93% and a negative net margin of 1,201.08%. The business had revenue of $2.30 million during the quarter, compared to analyst estimates of $1.48 million. During the same quarter in the previous year, the firm posted ($0.10) EPS. On average, analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning acquired 750,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were bought at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the acquisition, the insider directly owned 2,841,704 shares in the company, valued at $7,814,686. This trade represents a 35.86% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.78% of the company's stock.

Institutional Trading of Taysha Gene Therapies

Hedge funds have recently added to or reduced their stakes in the business. LPL Financial LLC bought a new stake in Taysha Gene Therapies during the 4th quarter valued at $104,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Taysha Gene Therapies in the 4th quarter worth $8,650,000. Hsbc Holdings PLC raised its stake in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after buying an additional 8,076 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Taysha Gene Therapies in the 4th quarter worth $41,000. Finally, Vanguard Group Inc. raised its stake in shares of Taysha Gene Therapies by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after buying an additional 641,305 shares in the last quarter. Institutional investors own 77.70% of the company's stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.